Confirms Receipt of Two Director Nominees from Daniel J. ManglessStockholders Are Not Required to Take Action at This TimeCELEBRATION, Fla., ...
Zevra Therapeutics’ Miplyffa approved for Niemann-Pick type C. Read why ZVRA stock presents both potential and risks for long ...
CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the “Company”), a commercial-stage company ...
CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the “Company”), a commercial-stage company focused on providing therapies to people living ...
March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the“Company”), a commercial-stage company focused on providing therapies to people living with ...
IntraBio's Aqneursa (levacetylleucine) has joined Zevra Therapeutics' Miplyffa (arimoclomol) for patients with Niemann-Pick type C (NPC), a rare genetic disease affecting around one in 100,000 ...
LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback